CAPS

Business Context and Reporting Period

Company: OrthoLogic Corp. (Note: Metadata listed "Capstone Holding Corp." but filing text confirms OrthoLogic Corp.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1998
Business Overview: OrthoLogic develops and markets orthopedic products, including the OL 1000 Bone Growth Stimulator and the OrthoRehab rental fleet. The company also holds a co-promotion agreement for Hyalgan and recently acquired an equity interest in Chrysalis BioTechnology.

Key Financial Metrics

Cash Flow: Net cash used in operating activities was $5.9 million. Net cash used in investing activities was $1.4 million. Net cash provided by financing activities was $0.3 million.

Material Changes vs. Prior Period

• Revenue: Increased 2.8% year-over-year for the six-month period, driven by the OrthoRehab rental fleet and Hyalgan sales, though Q2 revenue declined 4.4% compared to Q2 1997.
• Operating Expenses: Selling, General, and Administrative (SG&A) expenses surged $10.7 million to $41.2 million. This was primarily due to a $9.3 million increase in the allowance for doubtful accounts as management shifted collection focus to current sales and wrote off older receivables.
• Liquidity: Cash and cash equivalents dropped significantly from $7.8 million at year-end 1997 to $0.8 million at June 30, 1998. This decrease was driven by a $1.0 million payment on the co-promotion agreement, a $2.3 million increase in inventory, and capital expenditures for the rental fleet.
• Other Income: Declined to $0.1 million from $1.0 million in the prior year due to the absence of research grant revenue and reduced interest income from lower cash balances.

Guidance, Outlook, and Risks

• Capital Raise: Subsequent to the period end (July 13, 1998), the company completed a private placement of Series B Convertible Preferred Stock raising approximately $15 million (net ~$14 million) to fund new product opportunities (SpinaLogic, Chrysalin, Hyalgan) and business process re-engineering.
• Liquidity Outlook: Management anticipates existing cash and the $7.5 million line of credit will meet requirements for the next 12 months, though no assurance is given regarding future financing terms.
• Product Developments: Received FDA approval to change the label for the OL 1000 Bone Growth Stimulator to treat non-union fractures without a nine-month waiting period. Acquired an option to license Chrysalin for fracture healing, targeting FDA approval by 2000.
• Litigation Risks: Facing consolidated class action lawsuits alleging securities fraud regarding undisclosed FDA correspondence. The company moved to dismiss, but plaintiffs were granted leave to amend. Additionally, a former owner of acquired assets (DMTI) filed a lawsuit regarding breach of acquisition agreements and escrow funds.
• Year 2000 Compliance: Modification of significant applications is substantially complete; testing is planned for completion by December 31, 1998. Costs are not anticipated to be material.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of operations given the drop in cash to $0.8 million and the reliance on the recent $15 million private placement.
• Bad Debt Provision: Assess the impact of the $9.3 million one-time increase in the allowance for doubtful accounts on future earnings and the effectiveness of the new collection strategy.
• Debt Covenants: Review the terms of the $7.5 million revolving line of credit and the recent Series B Preferred Stock conversion terms and warrant exercise prices.
• Litigation Exposure: Monitor the status of the securities class action and the DMTI acquisition dispute, as outcomes could result in significant financial liability.
• Co-Promotion Liability: Confirm the remaining $2.0 million liability under the Sanofi co-promotion agreement and the associated royalty obligations.